4.6 Review

Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease

Journal

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Volume 56, Issue 1, Pages 5-18

Publisher

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2017-0120

Keywords

atherosclerosis; biomarkers; cardiovascular disease; inflammation; neutrophil gelatinase-associated lipocalin (NGAL)

Ask authors/readers for more resources

Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available